Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ding, Xuewei
PERSIST, NCT04982939: Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer	Recruiting	2	210	RoW	Sintilimab, IBI308, S-1, Oxaliplatin	Tianjin Medical University Cancer Institute and Hospital	Gastric Cancer, Perioperative, Sintilimab	06/23	06/24
AK104-IIT-C-N1-0036, NCT05974059: Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer	Not yet recruiting	2	20	RoW	Oxaliplatin, Capecitabine, Cadonilimab	Tianjin Medical University Cancer Institute and Hospital	Locally Advanced Unresectable Gastric Adenocarcinoma	08/24	08/24
NCT06560528: Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression	Recruiting	2	40	RoW	combination with Disitamab Vedotin and with Tislelizumab and Capecitabine	Tianjin Medical University Cancer Institute and Hospital	Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	09/27	09/28